TechFlow News, March 30: According to 36Kr, Weiyuan Synthesis, a synthetic biology R&D company, closed a $300 million Series A+ financing round in March 2026, with participation from Henan Investment Group’s Huirong Fund and Mr. Tan Ruiqing. Proceeds from this round will be used to expand the application boundaries of AI-driven biological computing, increase investment in core technology R&D, and accelerate scenario-specific deployment.
Meanwhile, Weiyuan Synthesis, in collaboration with Stanford University, Princeton University, Peking University, ByteDance, and NVIDIA, launched PoseX—an open collaborative platform—at ICLR 2026—designed to address molecular docking challenges in real-world scenarios. The platform systematically evaluated 24 mainstream methods. Test results show that top-performing AI docking methods (e.g., SurfDock) and co-folding methods (e.g., AlphaFold3) have comprehensively surpassed traditional physics-based models in both accuracy and robustness for cross-conformational docking tasks.
To date, Weiyuan Synthesis has completed R&D and industrialization of multiple products—including allulose, lutein, and mannitol—and is accelerating development of its methanol-based biomanufacturing product pipeline.
